H-CYTE (OTCMKTS:HCYTD) and INVO Fertility (NASDAQ:IVF) Critical Survey

INVO Fertility (NASDAQ:IVF) and H-CYTE (OTCMKTS:HCYTD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Valuation & Earnings

This table compares INVO Fertility and H-CYTE”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$6.94 million	0.38	-$9.10 million	($630.30)	0.00
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A

H-CYTE has lower revenue, but higher earnings than INVO Fertility.

Volatility and Risk

INVO Fertility has a beta of 2.65, indicating that its share price is 165% more volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Profitability

This table compares INVO Fertility and H-CYTE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-417.02%	N/A	-92.42%
H-CYTE	-450.40%	N/A	-777.68%

Analyst Ratings

This is a breakdown of current recommendations for INVO Fertility and H-CYTE, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1	0	0	1	2.50
H-CYTE	0	0	0	0	0.00

INVO Fertility presently has a consensus target price of $4.00, indicating a potential upside of 263.64%. Given INVO Fertility’s stronger consensus rating and higher probable upside, equities research analysts plainly believe INVO Fertility is more favorable than H-CYTE.

Insider & Institutional Ownership

12.0% of INVO Fertility shares are held by institutional investors. 0.7% of INVO Fertility shares are held by insiders. Comparatively, 5.2% of H-CYTE shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

INVO Fertility beats H-CYTE on 9 of the 11 factors compared between the two stocks.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.